Clinical Trials Logo

Gas Gangrene clinical trials

View clinical trials related to Gas Gangrene.

Filter by:
  • None
  • Page 1

NCT ID: NCT03147352 Completed - Clinical trials for Necrotizing Soft Tissue Infection

Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study

ProTreat
Start date: February 2013
Phase:
Study type: Observational [Patient Registry]

The investigators will analyze biomarkers related to the prognosis and treatment of necrotizing soft tissue infections (NSTI). The focus will be on whether certain endothelial and immune system biomarkers can function as markers of disease severity, mortality as well as the effects of hyperbaric oxygen therapy (HBOT). Biomarkers will be measured upon admission to an intensive care unit at Copenhagen University Hospital and during the following 3 days.

NCT ID: NCT02501382 Completed - Clinical trials for Necrotizing Soft Tissue Infection

Modulation of Biomarkers in Patients With Flesh-eating Bacterial Infections After With Hyperbaric Oxygen Treatment

BIONEC-II
Start date: February 2013
Phase:
Study type: Observational

The purpose of this study is to investigate the effects of hyperic oxygen treatment on the immune response in patients with necrotizing soft tissue infections

NCT ID: NCT02483650 Enrolling by invitation - Clinical trials for Carbon Monoxide Poisoning

Hyperbaric Oxygen Therapy Registry

HBOTR
Start date: January 2005
Phase:
Study type: Observational [Patient Registry]

The purpose of the Hyperbaric Oxygen Therapy Registry (HBOTR) is to provide real world patient outcome and side effect information from electronic health records submitted to a specialty specific hyperbaric registry as part of "Stage 2 of Meaningful Use," including data provided to meet PQRS requirements via the registry's QCDR mission. Goals include understanding the value of HBOT among patients treated for a variety of conditions in relation to the frequency and severity of HBOT side effects. While randomized, controlled trials can establish the efficacy of treatments like HBOT, because they routinely exclude patients with co-morbid conditions common to those patients seen in usual clinical practice, the results of RCTs are usually non-generalizable. Real world data can be used to better understand the effectiveness of HBOT among typical patients, as well as the risks associated with treatment.

NCT ID: NCT02180906 Completed - Clinical trials for Necrotizing Soft Tissue Infection

Biomarkers in Patients With Flesh-eating Bacterial Infections

BIONEC
Start date: February 2013
Phase: N/A
Study type: Observational

The purpose of this study is to investigate the immune response in patients with necrotizing soft tissue infections (NSTI). The investigation will focus on inflammatory and vasoactive biomarkers as prognostic markers of severity and mortality at admission to Rigshospitalet and the following 3 days

NCT ID: NCT02111161 Completed - Clinical trials for Necrotizing Soft Tissue Infection

Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial

INSTINCT
Start date: April 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to estimate the effect of intravenous polyspecific immunoglobulin G (IVIG) compared with placebo (saline) on the patient-reported outcome measure Physical Component Summary Score (PCS) of the SF-36 in patients with necrotizing soft tissue infections (NSTI).

NCT ID: NCT01794182 Completed - Ischemic Stroke Clinical Trials

Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

GAMES-RP
Start date: June 13, 2013
Phase: Phase 2
Study type: Interventional

This is a randomized, multi-center, prospective, double blind study. The primary objective is to assess the efficacy and safety of glyburide (RP-1127) compared to placebo in participants with a severe anterior circulation ischemic stroke who are likely to develop malignant edema.This objective will be addressed by comparing the proportion of glyburide treated particpants and placebo treated participants with a Day 90 modified Rankin Scale (mRS) ≤ 4 without decompressive craniectomy (DC). The secondary objective is to assess the efficacy of RP-1127 compared to placebo in participants with a severe anterior circulation ischemic stroke who were likely to develop malignant edema.